Page 235

Catalogue_WEB_WoP_Jun16

Pricing and Online Ordering at www.alphalabs.co.uk Clinical Chemistry C3/C4 (Turbidimetric) For the quantitative immunoturbidimetric determination of Complement Factor C3 (C3) or C4 in serum and plasma. C3 determination may aid the diagnosis and treatment of inflammatory disorders such as glomerulonephritis, rheumatoid arthritis and bacterial infections. C4 is useful in the diagnosis of pathologies such as immunocomplex diseases, systemic lupus erythematosus, autoimmune thyroiditis, juvenile dermatomyositis, bacterial and viral meningitis, streptococcal and staphylococcal sepsis and pneumonia. n Dual buffer with antibody preparation n Measuring range: C3: 20-500 mg/dL C4: 5-200 mg/dL n Open-vial stability: 60 days when stored at 2-8C Technical information: The determination is based on a turbidimetric reaction between a specific polyclonal antiserum and C3 or C4 in the presence of polyethylenglycol polymer (PEG). The change in absorbance caused by the immuno-complex is proportional to the concentration of the analyte in the sample. C3/C4 (Turbidimetric) Catalogue Number Description Pack Size 11060D C3 Turbidimetric Assay 2x50ml;2x1ml,1x10ml 11062D C4 Turbidimetric Assay 2x50ml;2x1ml,1x10ml 11200D Plasmaproteins Calibrator 3x1ml 11211A Immuno Control Set (2 levels) 2x(2x1)ml Sentinel C1 Esterase Inhibitor For quantitative immunoturbidimetric determination of C1 esterase inhibitor (C1 INH) in serum or plasma. The C1-inhibitor irreversibly binds to and inactivates C1r and C1s proteases in the C1 complex of the complement classical activation pathway. It also inactivates MASP-1 and MASP-2 proteases in the lectin pathway. C1-esterase inhibitor also inhibits proteases of the fibrinolytic, clotting and kinin pathways and is the most important physiological inhibitor of plasma kallikrein, fXIa and fXIIa. C1 esterase inhibitor determination is useful in the diagnosis of hereditary angioneurotic oedema that is due to an absolute decrease in the amount of C1 esterase inhibitor. n Dual buffer and antibody preparation n Measuring range: 5-120 mg/dL n Open-vial stability: 60 days at 2-8C Technical information: The anti-C1-esterase inhibitor polyclonal antiserum at optimal pH and in the presence of polyethyleneglycole polymer (PEG) will bind C1-esterase inhibitor within the sample. The antigen-antibody complex formed increases the turbidity of the test solution as measured at 340nm. The increase in turbidity is proportional to the concentration of C1 inhibitor in the sample. C1 Esterase Inhibitor Catalogue Number Description Pack Size 11052D C1 Esterase Inhibitor Assay 2x50ml, 2x1ml, 1x10ml 11200D Plasmaproteins Calibrator 3x1ml 11211A Immuno Control Set (2 levels) 2x(2x1)ml Sentinel Copper Direct colorimetric determination of copper without deproteinisation in serum and plasma. Divalent copper ions form complexes with proteins. The major functions of copper metalloproteins involve oxidation & reduction; most known copper containing enzymes bind and react directly with molecular oxygen. In plasma, approximately 95% of copper is bound to the ceruloplasmin, an oxidase with ferroxidase activity. There is evidence that marginal copper deficiency is associated with heart disease, bone and joint osteoarthritis and osteoporosis. Also decreased levels of copper result in a reduction of antioxidant protection. n Dual reconstituted reagent n Linearity: up to 500 μg/dL n On-board stability is typically 45 days n Includes standard Technical information: In pH 4.7 buffer, copper is released from the carrier protein ceruloplasmin and subsequently forms a stable coloured complex with 3,5-DiBr-PAESA 4-(3,5- dibromo-2-pyridylazo)-Nethyl-N-(3-sulfopropyl)aniline. The colour intensity of this complex is proportional to the amount of copper in the sample. Copper Catalogue Number Description Pack Size 17638H Copper Colorimetric Assay 5x20;21ml 16150 Clin Chem Control 1 6x5ml 16250 Clin Chem Control 2 6x5ml Sentinel Clinical Chemistry - C n email order sales@alphalabs.co.uk n freefax order 0800 614249 233


Catalogue_WEB_WoP_Jun16
To see the actual publication please follow the link above